Prof. Nagendra Kaushik
Kwangwoon University, South Korea
Prof. Nagendra Kaushik is working at the Department of Electrical and Biological Physics & Plasma Bioscience Research Center at Kwangwoon University, Seoul (South Korea) since 2011. His research work is primarily focused on plasma bioscience & medicine, plasma agriculture, plasma environment, cancer biology & immuno-modulations, plasma chemistry, nanobiotechnology, and biomaterials. He has published more than 150 high impact publications, including many in top-ranked journals such as Biomaterials (impact factor 15.6), Cancer Research (impact factor13.3), Journal of Advanced Research (impact factor 12.4), Green Chemistry (impact factor 11.3), Materials Today Bio (impact factor 10.7), Science of The Total Environment (impact factor 10.75) and Journal of Nanobiotechnology (impact factor 11.5) and Bioactive Materials (impact factor 17.3) and applied several product and process patents. His H-index is 34 and the I10 index is 74 with a total citation of around 5000. Prof. Nagendra is serving as the editor of more than 20 journals including Scientific Report, PloS One, IEEE Journals, Frontiers journals, and many others. He is also listed in World's Top 2% Scientists by Stanford University and Elsevier continuously since 2020.
Speech Title: "Plasma-Generated Nitric Oxide Water for Bio-medical Applications"
Abstract: This presentation elucidates the research behind nonthermal gas plasma techniques for decontamination, microbial inactivation, viral sterilization, and environmental protection. Aimed at creating a pathogen-free world, the focus is on industrial interventions to neutralize contaminants in soil, water, and air. Our laboratory investigates plasma-generated nitric oxide water and eco-friendly plasma-based nanomaterial synthesis, examining their biomedical applications. We introduce an innovative method using plasma-generated nitric oxide water for inactivating pathogens, including viruses and bacteria. This technique promotes sustainable agriculture and eco-friendly metal nanoparticle synthesis. Additionally, we explore its use in cosmetics and aesthetics, such as anti-aging treatments. These methods are cost-effective, environmentally responsible, and sustainable, making them viable for biological, environmental, and nanobiotechnological applications, with potential therapeutic and industrial uses. In summary, research into plasma-based, environmentally friendly methods shows promise for advancements in agriculture, bioscience, nanotechnology, and environmental sciences, highlighting their potential as sustainable and effective solutions for various applications.
Invited Speakers
Assoc. Prof. Anita Sukmawati
Universitas Muhammadiyah Surakarta, Indonesia
Anita Sukmawati is an associate professor in Faculty of Pharmacy, Universitas Muhammadiyah Surakarta, Indonesia. She gained her Ph.D degree from School of Pharmacy, University of Nottingham, UK, under Islamic Development Bank (IDB) Merit Scholarship. Currently, she teaches several subjects for undergraduate and postgraduate programs at her institution. She had published a number of research articles on drug delivery systems and dosage formulations for pharmaceutical and cosmetic preparations that use the most recent technologies. The ongoing research focuses on the utilization of beetroot (Beta vulgaris, Linn) components in microparticle formulations for cosmetic applications.
Speech Title: "Formulation and Stability Evaluation of Gels Containing Chitosan Microparticle Loaded Beetroot (Beta Vulgaris, Linn) for Topical Skin Brightening"
Abstract: The objective of this research is to investigate the effect of hydroxypropyl methylcellulose (HPMC) concentration as a gel base for chitosan microparticle containing beetroot (Beta vulgaris, Linn) toward gels stability and skin brightening effect. Ionic gelation was used to make microparticle (MP) using chitosan 1% solution and beetroot dry extract as active component. Scanning electron microscope (SEM) and active substance loading were used for physical characterisation. The MP then was added to HPMC-based gels at 0.5, 1.0, and 1.5% w/w. Gels were tested for viscosity, pH, and active component stability. Gels were tested for skin lightening on humans. Results reveal beetroot extract may be loaded into chitosan MP with a drug loading (DL) of 23.27 ± 0.057% w/w. HPMC gels had a pH of 5-5.4 and increased viscosity related with HPMC content. Gels showed colour instability after 6 cooling-heating cycles and decreased betanin levels on day 7 at 40 ± 2 °C and RH 75 ± 5%. HPMC 0.5% gel brightened human skin more than other HPMC gels. The 0.5% HPMC gel base had the smallest betanin reduction during the accelerated stability test, compared to the 1.0 and 1.5% HPMC gels. The formulation of chitosan microparticle gel loading beetroot extract with 0.5% HPMC gel base had brightened skin better than the other two formulae.
Assoc. Prof. Muhammad Ijaz
Qilu institute of Technology, China
Dr. Muhammad Ijaz, from Pakistan, graduated from Shandong University with a Ph.D. in Pharmacology. Currently, he is working as an associate Professor of Pharmacology at Qilu Institute of Technology. His main research interests include anti-cancer study and antihyperlipidemic study. He has published 12 Sci research papers and review articles in different well renowned international core Journals with high impact factors. In 2020, he was appointed as the Principal at the Apex college of Pharmacy, Pakistan. Shandong University awarded him the 'Outstanding Graduate 2017 Shandong University International Student', and '2019-2020 Winner of Shandong University Distinguished International Graduate Student Scholarship'. Moreover, He has published several articles on the vital 'the belt and road' initiative in China Daily and other print media forums. He has published an article on 'Life in China'and got third prize in 'My journey in SDU' writing/photo contest held by the International School, Shandong University. While being active in research, he has actively participated in the co-curricular activities. He enthusiastically participated in International Sports Gala and won the title of 'Champions' in the game of cricket.
Speech Title: "Screening of Active Ingredients from Wendan Decoction in Alleviating Palmitic Acid-Induced Endothelial Cell Injury"
Abstract: (1) Objective: Traditional Chinese
medicine (TCM) plays an important role in
the treatment of numerous illnesses. As a
classic Chinese medicine, Wendan Decoction
(WDD) encompasses a marvelous impact on the
remedy of hyperlipidemia. It is known that
hyperlipidemia leads to cardiovascular
injury, therefore anti-vascular endothelial
cell injury (AVECI) may be an underlying
molecular mechanism of WDD in the cure of
hyperlipidemia. However, there is no
relevant research on the effect of WDD on
vascular endothelial cells and its
pharmacodynamic substances. Therefore, the
purpose of this study was to investigate the
protective effect of WDD on vascular
endothelial cells. (2) Methods: The chemical
constituents of WDD were determined by
LC-MS/MS technology. The protective effects
of 16 batches of WDD on samples from human
umbilical vein endothelial cells (HUVECs)
were evaluated. Finally, gray relation
analysis (GRA) and partial least squares
regression (PLSR) were used to analyze the
potential correlation between chemical
ingredients and AVECI. (3) Results: The
results indicated that WDD had apparent
protective effect on endothelial cells, and
pharmacological properties in 16 batches of
WDD tests were apparently discrepant. The
GRA and PLSR showed that trigonelline,
liquiritin, hesperidin, hesperetin,
scopoletin, morin, quercetin,
isoliquiritigenin, liquiritigenin and
formononetin may be the active ingredients
of AVECI in WDD. (4) Conclusion: WDD has a
protective effect on endothelial cell injury
induced by palmitic acid, which may be
related to its component content. This
method was suitable for the search of active
components in classical TCM.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Previous Speakers
Prof. Buyong Ma
Shanghai Jiaotong University, China
Professor Buyong Ma has more than 25 years experiences in the computational studies of protein structure and function, protein engineering, and antibody-antigen recognition. He has proposed “conformation selection” theory which is widely used in explaining drug-target interaction. Dr. Ma received his Ph.D. in physical chemistry from the University of Georgia at Athens in 1995 and continued his postdoctoral training on computational chemistry. He joined NCI/NIH in 1998. In 2019, Dr. Ma accepted a tenured professor position in the school of pharmacy, Shanghai Jiaotong University, focusing on biological drug design. He has published more than 200 papers, with google citation of 21000 and H-index 66.
Prof. Walter Herzog
University of Calgary, Canada
Dr. Herzog did his undergraduate training in Physical Education at the Federal Technical Institute in Zurich, Switzerland (1979), completed his doctoral research in Biomechanics at the University of Iowa (USA) in 1985, and completed postdoctoral fellowships in Neuroscience and Biomechanics in Calgary, Canada in 1987. Currently, Dr. Herzog is a Professor of Biomechanics with appointments in Kinesiology, Medicine, Engineering, and Veterinary Medicine, holds the Canada Research Chair for Cellular and Molecular Biomechanics, and is appointed the Killam Memorial Chair for Inter-Disciplinary Research at the University of Calgary. His research interests are in musculoskeletal biomechanics with emphasis on mechanisms of muscle contraction focusing on the role of the structural protein titin, and the biomechanics of joints focusing on mechanisms of onset and progression of osteoarthritis. Dr. Herzog is the recipient of the Borelli Award from the American Society of Biomechanics, the Career Award from the Canadian Society for Biomechanics, the Dyson Award from the International Society of Biomechanics in Sports, the Muybridge Award from the International Society of Biomechanics, and recently received the Killam Prize in Engineering from the Canada Council for the Arts for his contributions to Biomedical research. He is the past president of the International, American and Canadian Societies for Biomechanics. He was inducted into the Royal Society of Canada in 2013.
Prof. Chang-Deng Hu
Purdue University, USA
Dr. Chang-Deng Hu is a Professor and Steve and Lee Ann Taglienti Chair in Pharmacy in the Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy. He also serves as Program Co-Leader of Cell Identify and Signaling and Program Co-Leader of Prostate Cancer Discovery Group in the Purdue University Center for Cancer Research. Dr. Hu received his M.D. from Bengbu Medical College, China and Ph.D. in molecular biology from Kobe University, Japan. Prior to his Ph.D. study, he also conducted his graduate study for M.S. degree in tumor immunology at Tongji Medical University, China. During his postdoctoral research at the University of Michigan, Dr. Hu pioneered the development of bimolecular fluorescence complementation (BiFC) technology for visualization of protein-protein interactions in live cells. His lab at Purdue has developed an integrated research program that involves technology development, biological discovery, and clinical translation. The current research focus in the lab is “Mechanism and targeting of therapy-induced neuroendocrine differentiation in prostate cancer.”
Assoc. Prof. Dan Li
Zhejiang University, China
Dan Li is an associated professor at the College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P. R. China. She received her PhD degree in Biochemistry and Molecular Biology from Marburg University, Germany in 2009. She then worked as a postdoctoral fellow in the research group of Prof. Dr. Roland K. Hartmann (Institute of Pharmaceutical Chemistry, Philipps-UniversityMarburg, Germany) from 2009 to 2010, and then Alexander von Humboldt fellowship in the research group of Prof. Dr. Albrecht Bindereif (Institute of Biochemistry, Justus-Liebig-University Giessen, Germany) from 2010 to 2013. Her research work is now focusing on design and discovery of small new-scaffold bioactive compounds targeting innovative target sites, especially on drugs targeting nucleic receptor.